Children’s medulloblastoma risk model using tumor genetic typing
Part of Cancer clinical trials.
This trial builds and tests a risk classification system for children with medulloblastoma using tumor genetic (molecular) testing. It may help doctors better predict risk and guide follow-up and treatment planning based on a child’s tumor type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 6 months to 18 years old (not a newborn).
- The diagnosis of medulloblastoma has been confirmed under the microscope (pathology test).
- Before surgery, your child has not had other treatment that affects this condition (like certain prior therapy).
- After surgery, the child’s ability to function is good (KPS score 70 or higher).
- You can provide tumor tissue for genetic/molecular typing, and the results can be done.
- Your child can have special MRI scans of the head and whole spine, with contrast (enhanced MRI).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying the genetic details of medulloblastoma tumors in children to find new, targeted treatments. If your child had surgery for medulloblastoma at our pediatric center, their tumor tissue may help us learn more.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
This study looks at genetic (DNA/molecular) features of malignant brain tumors in children. It may help doctors better understand tumor risk patterns and guide future treatment planning.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
Hear when a new Medulloblastoma, Childhood trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.